Beoordeling van de prijs van een geneesmiddel

Before admission to the insured package, the price of a medicine is usually assessed on the basis of the value of the medicine for the patient: a large effect size on health and survival may cost more than a small or uncertain effect. That seems like a fair starting point, but such ‘value-driven’ models sometimes lead to unreasonably high prices. This in turn leads to discussions about limitations within the healthcare budget and to delays in the accessibility of medicines. We argue that it would be more logical for different categories of medicines to base prices on average costs, possibly combined with a bonus for innovation: the so-called cost-plus method.

Conflict of interest and financial support: potential conflicts of interest have been reported for this article. ICMJE forms provided by the authors are available online along with the full text of this article.